Read More

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit In High-Risk Relapsed Or Refractory Acute Myeloid Leukemia Patients With TP53 Mutations Accepted For Oral Presentation At The European Bone Marrow Transplant Annual…

-  The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis-  Represents the

ATNM

Read More

Candel Therapeutics Announces Oral Presentation During The 5th Glioblastoma Drug Development Summit With Update On Phase 1b Clinical Trial Of CAN-3110 In Recurrent High-Grade Glioma; Expects To Initiate Investigational New Drug-Enabling Work In A Secon…

The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial. The serial procedures were well tolerated without observed dose-limiting toxicity. A second

CADL